The Management of Prostatic Obstruction: How to Determine the Best Options?

European Urology, Supplement

Volumn 2, Issue 8, 2003, Pages 13-19

  Roehrborn, C G ^a   McNicholas, T ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b LISTER HOSPITAL   (United Kingdom)

Author keywords

5 reductase inhibitors; Acute urinary retention; BPH; Dutasteride; MTOPS; Surgical intervention; 1 blockers

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HUMAN; IMPOTENCE; INCIDENCE; LIBIDO DISORDER; MALAISE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0344014122     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2003.09.010     Document Type: Conference Paper

References (16)

1. The MTOPS Research Group. The impact of medical therapy on the clinical progression of BPH: results of the MTOPS trial. Abstract presented at the American Urological Association Annual Meeting 2002.
2. Roehrborn CG. Personal communication.
3. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
4. de la Rosette JJ, Kortmann BB, Rossi C, et al. Long-term risk of retreatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002;167:1734-9.
5. Jaffe JS, Ginsberg PC, Harkaway RC. Prostate size and PSA predict failure in patients undergoing alpha blocker monotherapy. Abstract presented at the American Urological Association Annual Meeting 2001.
6. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
7. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
8. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, et al., for the PLESS Study Group. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride and placebo. Urology 1999;54:662-9.
9. Tewari A, Indudhara R, Shinohara K, Schalow E, Woods M, Lee R, et al. Comparison of transrectal ultrasound prostatic volume estimation with magnetic resonance imaging volume estimation and surgical specimen weight in patients with benign prostatic hyperplasia. J Clin Ultrasound 1996;24(4):169-74.
10. Boyle P, Roehrborn CG, Marks L, Vela-Navarette R, Nickel JC. The novel dual 5α-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV ≥30-40 cc and ≥40 cc. Eur Urol Suppl 2003;2(1):160 [Abstract 632].
11. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557-63.
12. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997:49:839-45.
13. GlaxoSmithKline. Data on file.
14. McNicholas T, Tammela T, Te A, Harkaway R. The novel dual 5α-reductase inhibitor dutasteride is well tolerated with the concomitant use of commonly prescribed cardiovascular medications and PDE-5 inhibitors. Eur Urol Suppl 2003;2(1):74 [Abstract 287].
15. Clark R, Huffman CS, Swerdloff RS, Matsumoto A. Potent DHT suppression by the novel dual 5α-reductase inhibitor dutasteride does not effect bone density, bone metabolism or lipid profiles in healthy men. Eur Urol Suppl 2003;2(1):160 [Abstract 630].
16. GlaxoSmithKline. Data on file.